BR0314912A - A method of producing a cell comprising a functionally inactive gpr54 gene, nucleic acid construct, composition, method for providing an indication of utility in the diagnosis of a disease or condition, use of a gpr54 polypeptide, an agonist, an antanogist or of a gpr54 polypeptide activity modulator - Google Patents

A method of producing a cell comprising a functionally inactive gpr54 gene, nucleic acid construct, composition, method for providing an indication of utility in the diagnosis of a disease or condition, use of a gpr54 polypeptide, an agonist, an antanogist or of a gpr54 polypeptide activity modulator

Info

Publication number
BR0314912A
BR0314912A BR0314912-9A BR0314912A BR0314912A BR 0314912 A BR0314912 A BR 0314912A BR 0314912 A BR0314912 A BR 0314912A BR 0314912 A BR0314912 A BR 0314912A
Authority
BR
Brazil
Prior art keywords
gpr54
diagnosis
indication
nucleic acid
composition
Prior art date
Application number
BR0314912-9A
Other languages
Portuguese (pt)
Inventor
Samuel Aparicio
William Colledge
John Dixon
Alan Hendrick
Sophie Messager
Rosemary Thresher
Dirk Zahn
Original Assignee
Paradigm Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224926A external-priority patent/GB0224926D0/en
Priority claimed from GB0314481A external-priority patent/GB0314481D0/en
Priority claimed from GB0320623A external-priority patent/GB0320623D0/en
Application filed by Paradigm Therapeutics Ltd filed Critical Paradigm Therapeutics Ltd
Publication of BR0314912A publication Critical patent/BR0314912A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Animal Husbandry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

"MéTODO PARA PRODUZIR UMA CéLULA COMPREENDENDO UM GENE GPR54 FUNCIONALMENTE INATIVO, CONSTRUCTO DE áCIDO NUCLéICO, COMPOSIçãO, MéTODO PARA PROVER UMA INDICAçãO DE UTILIDADE NO DIAGNóSTICO DE UMA DOENçA OU DE UMA CONDIçãO, USO DE UM POLIPEPTìDIO GPR54, DE UM AGONISTA, DE UM ANTAGONISTA OU DE UM MODULADOR DA ATIVIDADE DO POLIPEPTìDEO GPR54". A presente invenção refere-se ao uso de um receptor do tipo galanina e/ou ligantes dos mesmos na manipulação do eixo hormonal pituitário e dos sistemas reprodutivos."METHOD FOR MAKING A CELL UNDERSTANDING A FUNCTIONALLY INACTIVE GPR54 GENE, NUCLEIC ACID CONSTRUCTION, COMPOSITION, METHOD TO PROVIDE AN INDICATION OF UTILITY OF A DIAGNOSIS, A GENTON DIAGNOSIS, OR A GPR54 POLYPEPTID ACTIVITY MODULATOR ". The present invention relates to the use of a galanin-like receptor and / or ligands thereof in manipulation of the pituitary hormone axis and reproductive systems.

BR0314912-9A 2002-10-25 2003-10-17 A method of producing a cell comprising a functionally inactive gpr54 gene, nucleic acid construct, composition, method for providing an indication of utility in the diagnosis of a disease or condition, use of a gpr54 polypeptide, an agonist, an antanogist or of a gpr54 polypeptide activity modulator BR0314912A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0224926A GB0224926D0 (en) 2002-10-25 2002-10-25 Harry potter
GB0314481A GB0314481D0 (en) 2003-06-20 2003-06-20 Harry Potter
US49534003P 2003-08-15 2003-08-15
US49996303P 2003-09-03 2003-09-03
GB0320623A GB0320623D0 (en) 2003-09-03 2003-09-03 Harry Potter
PCT/GB2003/004479 WO2004038021A1 (en) 2002-10-25 2003-10-17 Gpr54 knock-out mammals and screening methods using them

Publications (1)

Publication Number Publication Date
BR0314912A true BR0314912A (en) 2005-08-02

Family

ID=32180724

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0314912-9A BR0314912A (en) 2002-10-25 2003-10-17 A method of producing a cell comprising a functionally inactive gpr54 gene, nucleic acid construct, composition, method for providing an indication of utility in the diagnosis of a disease or condition, use of a gpr54 polypeptide, an agonist, an antanogist or of a gpr54 polypeptide activity modulator

Country Status (12)

Country Link
US (1) US20060015954A1 (en)
EP (1) EP1554382B1 (en)
JP (1) JP2006513723A (en)
KR (1) KR20050042826A (en)
AT (1) ATE429496T1 (en)
AU (1) AU2003301569A1 (en)
BR (1) BR0314912A (en)
CA (1) CA2503164A1 (en)
DE (1) DE60327344D1 (en)
MX (1) MXPA05004380A (en)
SG (1) SG155056A1 (en)
WO (1) WO2004038021A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2511858A1 (en) 2002-12-26 2004-07-29 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
CA2518541C (en) 2003-03-12 2013-05-21 Takeda Pharmaceutical Company Limited Gonadal function improving agents
NZ552029A (en) 2004-06-25 2009-01-31 Takeda Pharmaceutical Metastin derivatives and use thereof
WO2006047302A1 (en) * 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
AR058584A1 (en) 2005-12-22 2008-02-13 Takeda Pharmaceutical METASTININE DERIVATIVES AND USE OF THE SAME
TWI404726B (en) 2006-10-25 2013-08-11 Takeda Pharmaceutical Metastin derivatives and use thereof
US8716228B2 (en) 2009-05-27 2014-05-06 Yeda Research And Development Co. Ltd. GPR54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
KR20150100651A (en) * 2012-10-30 2015-09-02 리컴비네틱스 인코포레이티드 Control of sexual maturation in animals
CN115746146B (en) * 2022-08-31 2024-05-31 安徽农业大学 GnRH recombinant protein antigen, mammal castration recombinant protein vaccine and preparation method

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042486A1 (en) * 1999-12-08 2001-06-14 Smithkline Beecham Corporation Axor12
US20020106766A1 (en) * 2000-08-16 2002-08-08 Nabil Elshourbagy Molecular cloning of a galanine-like 7 transmembrane receptor (AXOR12 RAT)
EP1363655A4 (en) * 2000-12-18 2005-04-06 Merck & Co Inc Isolated nucleic acid molecules encoding a human and mouse g protein-coupled receptor - gpr54; encoded proteins, cells transformed therewith and uses thereof

Also Published As

Publication number Publication date
WO2004038021A1 (en) 2004-05-06
ATE429496T1 (en) 2009-05-15
EP1554382B1 (en) 2009-04-22
MXPA05004380A (en) 2005-11-23
CA2503164A1 (en) 2004-05-06
JP2006513723A (en) 2006-04-27
EP1554382A1 (en) 2005-07-20
SG155056A1 (en) 2009-09-30
KR20050042826A (en) 2005-05-10
WO2004038021A8 (en) 2004-09-16
US20060015954A1 (en) 2006-01-19
DE60327344D1 (en) 2009-06-04
AU2003301569A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
Frolik et al. Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts.
Dalman et al. Retinoic acid receptor belongs to a subclass of nuclear receptors that do not form" docking" complexes with hsp90
Benecke et al. Synergy between estrogen receptor α activation functions AF1 and AF2 mediated by transcription intermediary factor TIF2
Lehnert et al. Embryonic expression pattern of TGF beta type-1 RNA suggests both paracrine and autocrine mechanisms of action
Pottratz et al. 17 beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism.
BR0314912A (en) A method of producing a cell comprising a functionally inactive gpr54 gene, nucleic acid construct, composition, method for providing an indication of utility in the diagnosis of a disease or condition, use of a gpr54 polypeptide, an agonist, an antanogist or of a gpr54 polypeptide activity modulator
Zhao et al. Aromatase P450 gene expression in human adipose tissue. Role of a Jak/STAT pathway in regulation of the adipose-specific promoter
Corps et al. Receptors for epidermal growth factor and insulin-like growth factor-I on preimplantation trophoderm of the pig
Stoica et al. Regulation of estrogen receptor‐α gene expression by 1, 25‐dihydroxyvitamin D in MCF‐7 cells
Taton et al. General inhibition by transforming growth factor β1 of thyrotropin and cAMP responses in human thyroid cells in primary culture
Reynaud et al. A familial form of congenital hypopituitarism due to a PROP1 mutation in a large kindred: phenotypic and in vitro functional studies
Erspamer et al. Sauvagine, a new polypeptide from Phyllomedusa sauvagei skin. Occurrence in various Phyllomedusa species and pharmacological actions on rat blood pressure and diuresis.
Marroqui et al. Leptin downregulates expression of the gene encoding glucagon in alphaTC1-9 cells and mouse islets
Sundaram et al. USP19-deubiquitinating enzyme regulates levels of major myofibrillar proteins in L6 muscle cells
WO2000015826A3 (en) Leptin induced genes
Lockwood et al. Progestin-epidermal growth factor regulation of tissue factor expression during decidualization of human endometrial stromal cells
Plisov et al. Cited1 is a bifunctional transcriptional cofactor that regulates early nephronic patterning
Wang et al. A novel molecule in human cyclic endometrium: LncRNA TUNAR is involved in embryo implantation
Hampl et al. Levels and interactions of p27, cyclin D3, and CDK4 during the formation and maintenance of the corpus luteum in mice
TR200103339T2 (en) New LHRH-antagonists with improved solubility features.
Hakimi et al. Biochemical and functional analysis of soluble human interleukin-2 receptor produced in rodent cells. Solid-phase reconstitution of a receptor-ligand binding reaction.
EP0789076A3 (en) G protein coupled receptor proteins, their production and use
Casslen Uterine fluid volume. Cyclic variations and possible extrauterine contributions.
DE60322882D1 (en) T CELL SUBPOPULATION FOR REGULATING DARMIMMUNITY
Lamy et al. Control of protein synthesis by thyrotropin and epidermal growth factor in human thyrocytes: role of morphological changes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2069 DE 31/08/2010.